Compare PDX & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDX | AURA |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | NY | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 945.1M | 797.5M |
| IPO Year | 2018 | 2021 |
| Metric | PDX | AURA |
|---|---|---|
| Price | $20.22 | $6.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 105.8K | ★ 612.3K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.47 | $4.73 |
| 52 Week High | $25.21 | $9.54 |
| Indicator | PDX | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 20.28 | 25.95 |
| Support Level | $19.95 | $5.30 |
| Resistance Level | $20.36 | $6.27 |
| Average True Range (ATR) | 0.33 | 0.29 |
| MACD | -0.16 | -0.12 |
| Stochastic Oscillator | 2.01 | 1.85 |
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.